{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:04:56Z","timestamp":1765422296056},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,26]]},"DOI":"10.7759\/cureus.29600","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T13:35:48Z","timestamp":1664199348000},"source":"Crossref","is-referenced-by-count":2,"title":["Ocular Adverse Effects of Gefitinib: A Case Report"],"prefix":"10.7759","author":[{"given":"Sandhya","family":"Jeria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana R","family":"Thool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Daigavane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samyak","family":"Ganjre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3310\/hta14suppl2\/10","article-title":"Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer","volume":"14","author":"Brown T","year":"2010","unstructured":"Brown T, Boland A, Bagust A, et al.. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess. 2010, 14:71-9. 10.3310\/hta14suppl2\/10","journal-title":"Health Technol Assess"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.05.005","article-title":"Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders","volume":"40","author":"Agustoni F","year":"2014","unstructured":"Agustoni F, Platania M, Vitali M, et al.. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014, 40:197-203. 10.1016\/j.ctrv.2013.05.005","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials","volume":"19","author":"Tullo AB","year":"2005","unstructured":"Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005, 19:729-38. 10.1038\/sj.eye.6701630","journal-title":"Eye (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31818fdbc6","article-title":"Persistent corneal epithelial defect associated with erlotinib treatment","volume":"28","author":"Johnson KS","year":"2009","unstructured":"Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea. 2009, 28:706-7. 10.1097\/ICO.0b013e31818fdbc6","journal-title":"Cornea"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02518.x","article-title":"The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?","volume":"91","author":"Ho WL","year":"2013","unstructured":"Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?. Acta Ophthalmol. 2013, 91:604-9. 10.1111\/j.1755-3768.2012.02518.x","journal-title":"Acta Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/379132","article-title":"Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report","volume":"2012","author":"Ibrahim E","year":"2012","unstructured":"Ibrahim E, Dean WH, Price N, Gomaa A, Ayre G, Guglani S, Sallam A. Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report. Case Rep Ophthalmol Med. 2012, 2012:379132. 10.1155\/2012\/379132","journal-title":"Case Rep Ophthalmol Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000514696","article-title":"Bilateral severe corneal ulcer in a patient with lung adenocarcinoma treated with gefitinib","volume":"12","author":"Gozzi F","year":"2021","unstructured":"Gozzi F, Tiseo M, Facchinetti F, Gandolfi S, Rubino P. Bilateral severe corneal ulcer in a patient with lung adenocarcinoma treated with gefitinib. Case Rep Ophthalmol. 2021, 12:288-92. 10.1159\/000514696","journal-title":"Case Rep Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_325_18","article-title":"Clinical profile of cutaneous adverse effects of epidermal growth factor receptor inhibitors: a prospective observational study of 76 cases","volume":"10","author":"Saraswat N","year":"2019","unstructured":"Saraswat N, Sood A, Kumar D, Verma R, Sushil K. Clinical profile of cutaneous adverse effects of epidermal growth factor receptor inhibitors: a prospective observational study of 76 cases. Indian Dermatol Online J. 2019, 10:251-5. 10.4103\/idoj.IDOJ_325_18","journal-title":"Indian Dermatol Online J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture ME","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, et al.. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011, 19:1079-95. 10.1007\/s00520-011-1197-6","journal-title":"Support Care Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115294-ocular-adverse-effects-of-gefitinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:57Z","timestamp":1707508077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115294-ocular-adverse-effects-of-gefitinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.29600","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}